 | • レポートコード：MRC2Q12-19285 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、眼咽頭筋ジストロフィー（OPMD）の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に眼咽頭筋ジストロフィー（OPMD）のグローバル市場のxxx％を占める「錠剤」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院薬局」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 眼咽頭筋ジストロフィー（OPMD）の中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの眼咽頭筋ジストロフィー（OPMD）市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 眼咽頭筋ジストロフィー（OPMD）のグローバル主要プレイヤーには、Benitec Biopharma Inc.、Bioblast Pharma、BioMarin、PTC Therapeutics、NS Pharma、Nobelpharma Co., Ltd、Santhera Pharmaceuticals、Pfizer Inc.、Marathon Pharmaceuticals、Fibrogen、Bristol-Myers Squibb、Sarepta Therapeutics、GSKなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 眼咽頭筋ジストロフィー（OPMD）市場は、種類と用途によって区分されます。世界の眼咽頭筋ジストロフィー（OPMD）市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 錠剤、カプセル剤、注射剤、その他 【用途別セグメント】 病院薬局、小売店薬局、オンライン薬局 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 眼咽頭筋ジストロフィー（OPMD）製品概要 - 種類別市場（錠剤、カプセル剤、注射剤、その他） - 用途別市場（病院薬局、小売店薬局、オンライン薬局） - 調査の目的 ・エグゼクティブサマリー - 世界の眼咽頭筋ジストロフィー（OPMD）販売量予測2017-2028 - 世界の眼咽頭筋ジストロフィー（OPMD）売上予測2017-2028 - 眼咽頭筋ジストロフィー（OPMD）の地域別販売量 - 眼咽頭筋ジストロフィー（OPMD）の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別眼咽頭筋ジストロフィー（OPMD）販売量 - 主要メーカー別眼咽頭筋ジストロフィー（OPMD）売上 - 主要メーカー別眼咽頭筋ジストロフィー（OPMD）価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（錠剤、カプセル剤、注射剤、その他） - 眼咽頭筋ジストロフィー（OPMD）の種類別販売量 - 眼咽頭筋ジストロフィー（OPMD）の種類別売上 - 眼咽頭筋ジストロフィー（OPMD）の種類別価格 ・用途別市場規模（病院薬局、小売店薬局、オンライン薬局） - 眼咽頭筋ジストロフィー（OPMD）の用途別販売量 - 眼咽頭筋ジストロフィー（OPMD）の用途別売上 - 眼咽頭筋ジストロフィー（OPMD）の用途別価格 ・北米市場 - 北米の眼咽頭筋ジストロフィー（OPMD）市場規模（種類別、用途別） - 主要国別の眼咽頭筋ジストロフィー（OPMD）市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの眼咽頭筋ジストロフィー（OPMD）市場規模（種類別、用途別） - 主要国別の眼咽頭筋ジストロフィー（OPMD）市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の眼咽頭筋ジストロフィー（OPMD）市場規模（種類別、用途別） - 主要国別の眼咽頭筋ジストロフィー（OPMD）市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の眼咽頭筋ジストロフィー（OPMD）市場規模（種類別、用途別） - 主要国別の眼咽頭筋ジストロフィー（OPMD）市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの眼咽頭筋ジストロフィー（OPMD）市場規模（種類別、用途別） - 主要国別の眼咽頭筋ジストロフィー（OPMD）市場規模（トルコ、サウジアラビア） ・企業情報 Benitec Biopharma Inc.、Bioblast Pharma、BioMarin、PTC Therapeutics、NS Pharma、Nobelpharma Co., Ltd、Santhera Pharmaceuticals、Pfizer Inc.、Marathon Pharmaceuticals、Fibrogen、Bristol-Myers Squibb、Sarepta Therapeutics、GSK ・産業チェーン及び販売チャネル分析 - 眼咽頭筋ジストロフィー（OPMD）の産業チェーン分析 - 眼咽頭筋ジストロフィー（OPMD）の原材料 - 眼咽頭筋ジストロフィー（OPMD）の生産プロセス - 眼咽頭筋ジストロフィー（OPMD）の販売及びマーケティング - 眼咽頭筋ジストロフィー（OPMD）の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 眼咽頭筋ジストロフィー（OPMD）の産業動向 - 眼咽頭筋ジストロフィー（OPMD）のマーケットドライバー - 眼咽頭筋ジストロフィー（OPMD）の課題 - 眼咽頭筋ジストロフィー（OPMD）の阻害要因 ・主な調査結果 |
Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.
Market Analysis and Insights: Global Oculopharyngeal Muscular Dystrophy (OPMD) Market
Due to the COVID-19 pandemic, the global Oculopharyngeal Muscular Dystrophy (OPMD) market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Tablets accounting for % of the Oculopharyngeal Muscular Dystrophy (OPMD) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period.
China Oculopharyngeal Muscular Dystrophy (OPMD) market size is valued at US$ million in 2021, while the US and Europe Oculopharyngeal Muscular Dystrophy (OPMD) are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Oculopharyngeal Muscular Dystrophy (OPMD) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) include Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Oculopharyngeal Muscular Dystrophy (OPMD) Scope and Segment
Oculopharyngeal Muscular Dystrophy (OPMD) market is segmented By Type and By Application. Players, stakeholders, and other participants in the global Oculopharyngeal Muscular Dystrophy (OPMD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast By Type and By Application for the period 2017-2028.
Segment By Type
Tablets
Capsules
Injectable
Other
Segment By Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Company
Benitec Biopharma Inc.
Bioblast Pharma
BioMarin
PTC Therapeutics
NS Pharma
Nobelpharma Co., Ltd
Santhera Pharmaceuticals
Pfizer Inc.
Marathon Pharmaceuticals
Fibrogen
Bristol-Myers Squibb
Sarepta Therapeutics
GSK
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
1 Study Coverage
1.1 Oculopharyngeal Muscular Dystrophy (OPMD) Product Introduction
1.2 Market By Type
1.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Growth Rate By Type, 2017 VS 2021 VS 2028
1.2.2 Tablets
1.2.3 Capsules
1.2.4 Injectable
1.2.5 Other
1.3 Market By Application
1.3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Growth Rate By Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Estimates and Forecasts 2017-2028
2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Estimates and Forecasts 2017-2028
2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region
2.4.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2017-2022)
2.4.2 Global Sales Oculopharyngeal Muscular Dystrophy (OPMD) by Region (2023-2028)
2.5 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region
2.5.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2017-2022)
2.5.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Manufacturers
3.1.1 Global Top Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturers by Sales (2017-2022)
3.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) in 2021
3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Manufacturers
3.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Manufacturers (2017-2022)
3.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Oculopharyngeal Muscular Dystrophy (OPMD) Revenue in 2021
3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size By Type
4.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type
4.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Historical Sales By Type (2017-2022)
4.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecasted Sales By Type (2023-2028)
4.1.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2028)
4.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type
4.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Historical Revenue By Type (2017-2022)
4.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecasted Revenue By Type (2023-2028)
4.2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Type (2017-2028)
4.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price By Type
4.3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price By Type (2017-2022)
4.3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price Forecast By Type (2023-2028)
5 Market Size By Application
5.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application
5.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Historical Sales By Application (2017-2022)
5.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecasted Sales By Application (2023-2028)
5.1.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2028)
5.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application
5.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Historical Revenue By Application (2017-2022)
5.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecasted Revenue By Application (2023-2028)
5.2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Application (2017-2028)
5.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price By Application
5.3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price By Application (2017-2022)
5.3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price Forecast By Application (2023-2028)
6 North America
6.1 North America Oculopharyngeal Muscular Dystrophy (OPMD) Market Size By Type
6.1.1 North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2028)
6.1.2 North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2028)
6.2 North America Oculopharyngeal Muscular Dystrophy (OPMD) Market Size By Application
6.2.1 North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2028)
6.2.2 North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2028)
6.3 North America Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country
6.3.1 North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2028)
6.3.2 North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Market Size By Type
7.1.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2028)
7.1.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2028)
7.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Market Size By Application
7.2.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2028)
7.2.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2028)
7.3 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country
7.3.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2028)
7.3.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Market Size By Type
8.1.1 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2028)
8.1.2 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2028)
8.2 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Market Size By Application
8.2.1 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2028)
8.2.2 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2028)
8.3 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Region
8.3.1 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2017-2028)
8.3.2 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Market Size By Type
9.1.1 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2028)
9.1.2 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2028)
9.2 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Market Size By Application
9.2.1 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2028)
9.2.2 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2028)
9.3 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country
9.3.1 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2028)
9.3.2 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Market Size By Type
10.1.1 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2028)
10.1.2 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2028)
10.2 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Market Size By Application
10.2.1 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2028)
10.2.2 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2028)
10.3 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country
10.3.1 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2028)
10.3.2 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Benitec Biopharma Inc.
11.1.1 Benitec Biopharma Inc. Corporation Information
11.1.2 Benitec Biopharma Inc. Overview
11.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Benitec Biopharma Inc. Recent Developments
11.2 Bioblast Pharma
11.2.1 Bioblast Pharma Corporation Information
11.2.2 Bioblast Pharma Overview
11.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bioblast Pharma Recent Developments
11.3 BioMarin
11.3.1 BioMarin Corporation Information
11.3.2 BioMarin Overview
11.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 BioMarin Recent Developments
11.4 PTC Therapeutics
11.4.1 PTC Therapeutics Corporation Information
11.4.2 PTC Therapeutics Overview
11.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 PTC Therapeutics Recent Developments
11.5 NS Pharma
11.5.1 NS Pharma Corporation Information
11.5.2 NS Pharma Overview
11.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 NS Pharma Recent Developments
11.6 Nobelpharma Co., Ltd
11.6.1 Nobelpharma Co., Ltd Corporation Information
11.6.2 Nobelpharma Co., Ltd Overview
11.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Nobelpharma Co., Ltd Recent Developments
11.7 Santhera Pharmaceuticals
11.7.1 Santhera Pharmaceuticals Corporation Information
11.7.2 Santhera Pharmaceuticals Overview
11.7.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Santhera Pharmaceuticals Recent Developments
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Corporation Information
11.8.2 Pfizer Inc. Overview
11.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Pfizer Inc. Recent Developments
11.9 Marathon Pharmaceuticals
11.9.1 Marathon Pharmaceuticals Corporation Information
11.9.2 Marathon Pharmaceuticals Overview
11.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Marathon Pharmaceuticals Recent Developments
11.10 Fibrogen
11.10.1 Fibrogen Corporation Information
11.10.2 Fibrogen Overview
11.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Fibrogen Recent Developments
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Corporation Information
11.11.2 Bristol-Myers Squibb Overview
11.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Bristol-Myers Squibb Recent Developments
11.12 Sarepta Therapeutics
11.12.1 Sarepta Therapeutics Corporation Information
11.12.2 Sarepta Therapeutics Overview
11.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Sarepta Therapeutics Recent Developments
11.13 GSK
11.13.1 GSK Corporation Information
11.13.2 GSK Overview
11.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 GSK Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Oculopharyngeal Muscular Dystrophy (OPMD) Industry Chain Analysis
12.2 Oculopharyngeal Muscular Dystrophy (OPMD) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Oculopharyngeal Muscular Dystrophy (OPMD) Production Mode & Process
12.4 Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Marketing
12.4.1 Oculopharyngeal Muscular Dystrophy (OPMD) Sales Channels
12.4.2 Oculopharyngeal Muscular Dystrophy (OPMD) Distributors
12.5 Oculopharyngeal Muscular Dystrophy (OPMD) Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Oculopharyngeal Muscular Dystrophy (OPMD) Industry Trends
13.2 Oculopharyngeal Muscular Dystrophy (OPMD) Market Drivers
13.3 Oculopharyngeal Muscular Dystrophy (OPMD) Market Challenges
13.4 Oculopharyngeal Muscular Dystrophy (OPMD) Market Restraints
14 Key Findings in The Global Oculopharyngeal Muscular Dystrophy (OPMD) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Growth Rate By Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Tablets
Table 3. Major Manufacturers of Capsules
Table 4. Major Manufacturers of Injectable
Table 5. Major Manufacturers of Other
Table 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Growth Rate By Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2017-2022) & (K Units)
Table 9. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2017-2022)
Table 10. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2023-2028) & (K Units)
Table 11. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2023-2028)
Table 12. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region (2017-2022)
Table 14. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region (2023-2028)
Table 16. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Manufacturers (2017-2022) & (K Units)
Table 17. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Manufacturers (2017-2022)
Table 18. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Manufacturers (2017-2022)
Table 20. Oculopharyngeal Muscular Dystrophy (OPMD) Price by Manufacturers (2017-2022) &(US$/Unit)
Table 21. Global Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Oculopharyngeal Muscular Dystrophy (OPMD) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oculopharyngeal Muscular Dystrophy (OPMD) as of 2021)
Table 23. Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 25. Date of Manufacturers Enter into Oculopharyngeal Muscular Dystrophy (OPMD) Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2022) & (K Units)
Table 28. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2023-2028) & (K Units)
Table 29. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share By Type (2017-2022)
Table 30. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share By Type (2023-2028)
Table 31. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2022) & (US$ Million)
Table 32. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2023-2028) & (US$ Million)
Table 33. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share By Type (2017-2022)
Table 34. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share By Type (2023-2028)
Table 35. Oculopharyngeal Muscular Dystrophy (OPMD) Price By Type (2017-2022) & (US$/Unit)
Table 36. Global Oculopharyngeal Muscular Dystrophy (OPMD) Price Forecast By Type (2023-2028) & (US$/Unit)
Table 37. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2022) & (K Units)
Table 38. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2023-2028) & (K Units)
Table 39. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share By Application (2017-2022)
Table 40. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share By Application (2023-2028)
Table 41. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2022) & (US$ Million)
Table 42. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2023-2028) & (US$ Million)
Table 43. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share By Application (2017-2022)
Table 44. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share By Application (2023-2028)
Table 45. Oculopharyngeal Muscular Dystrophy (OPMD) Price By Application (2017-2022) & (US$/Unit)
Table 46. Global Oculopharyngeal Muscular Dystrophy (OPMD) Price Forecast By Application (2023-2028) & (US$/Unit)
Table 47. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2022) & (K Units)
Table 48. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2023-2028) & (K Units)
Table 49. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2022) & (US$ Million)
Table 50. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2023-2028) & (US$ Million)
Table 51. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2022) & (K Units)
Table 52. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2023-2028) & (K Units)
Table 53. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2022) & (US$ Million)
Table 54. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2023-2028) & (US$ Million)
Table 55. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022) & (K Units)
Table 56. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2023-2028) & (K Units)
Table 57. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2022) & (K Units)
Table 60. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2023-2028) & (K Units)
Table 61. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2022) & (US$ Million)
Table 62. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2023-2028) & (US$ Million)
Table 63. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2022) & (K Units)
Table 64. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2023-2028) & (K Units)
Table 65. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2022) & (US$ Million)
Table 66. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2023-2028) & (US$ Million)
Table 67. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022) & (K Units)
Table 68. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2023-2028) & (K Units)
Table 69. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2022) & (K Units)
Table 72. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2023-2028) & (K Units)
Table 73. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2022) & (K Units)
Table 76. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2023-2028) & (K Units)
Table 77. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2017-2022) & (K Units)
Table 80. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2023-2028) & (K Units)
Table 81. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2022) & (K Units)
Table 84. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2023-2028) & (K Units)
Table 85. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2022) & (US$ Million)
Table 86. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2023-2028) & (US$ Million)
Table 87. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2022) & (K Units)
Table 88. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2023-2028) & (K Units)
Table 89. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2022) & (US$ Million)
Table 90. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2023-2028) & (US$ Million)
Table 91. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022) & (K Units)
Table 92. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2023-2028) & (K Units)
Table 93. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2022) & (K Units)
Table 96. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2023-2028) & (K Units)
Table 97. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2022) & (K Units)
Table 100. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2023-2028) & (K Units)
Table 101. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022) & (K Units)
Table 104. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2023-2028) & (K Units)
Table 105. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2023-2028) & (US$ Million)
Table 107. Benitec Biopharma Inc. Corporation Information
Table 108. Benitec Biopharma Inc. Description and Major Businesses
Table 109. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 110. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Benitec Biopharma Inc. Recent Developments
Table 112. Bioblast Pharma Corporation Information
Table 113. Bioblast Pharma Description and Major Businesses
Table 114. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 115. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Bioblast Pharma Recent Developments
Table 117. BioMarin Corporation Information
Table 118. BioMarin Description and Major Businesses
Table 119. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 120. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. BioMarin Recent Developments
Table 122. PTC Therapeutics Corporation Information
Table 123. PTC Therapeutics Description and Major Businesses
Table 124. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 125. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. PTC Therapeutics Recent Developments
Table 127. NS Pharma Corporation Information
Table 128. NS Pharma Description and Major Businesses
Table 129. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 130. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. NS Pharma Recent Developments
Table 132. Nobelpharma Co., Ltd Corporation Information
Table 133. Nobelpharma Co., Ltd Description and Major Businesses
Table 134. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 135. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Nobelpharma Co., Ltd Recent Developments
Table 137. Santhera Pharmaceuticals Corporation Information
Table 138. Santhera Pharmaceuticals Description and Major Businesses
Table 139. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 140. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Santhera Pharmaceuticals Recent Developments
Table 142. Pfizer Inc. Corporation Information
Table 143. Pfizer Inc. Description and Major Businesses
Table 144. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 145. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Pfizer Inc. Recent Developments
Table 147. Marathon Pharmaceuticals Corporation Information
Table 148. Marathon Pharmaceuticals Description and Major Businesses
Table 149. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 150. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Marathon Pharmaceuticals Recent Developments
Table 152. Fibrogen Corporation Information
Table 153. Fibrogen Description and Major Businesses
Table 154. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 155. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Fibrogen Recent Developments
Table 157. Bristol-Myers Squibb Corporation Information
Table 158. Bristol-Myers Squibb Description and Major Businesses
Table 159. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 160. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Bristol-Myers Squibb Recent Developments
Table 162. Sarepta Therapeutics Corporation Information
Table 163. Sarepta Therapeutics Description and Major Businesses
Table 164. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 165. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Sarepta Therapeutics Recent Developments
Table 167. GSK Corporation Information
Table 168. GSK Description and Major Businesses
Table 169. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 170. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. GSK Recent Developments
Table 172. Key Raw Materials Lists
Table 173. Raw Materials Key Suppliers Lists
Table 174. Oculopharyngeal Muscular Dystrophy (OPMD) Distributors List
Table 175. Oculopharyngeal Muscular Dystrophy (OPMD) Customers List
Table 176. Oculopharyngeal Muscular Dystrophy (OPMD) Market Trends
Table 177. Oculopharyngeal Muscular Dystrophy (OPMD) Market Drivers
Table 178. Oculopharyngeal Muscular Dystrophy (OPMD) Market Challenges
Table 179. Oculopharyngeal Muscular Dystrophy (OPMD) Market Restraints
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
List of Figures
Figure 1. Oculopharyngeal Muscular Dystrophy (OPMD) Product Picture
Figure 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Share By Type in 2021 & 2028
Figure 3. Tablets Product Picture
Figure 4. Capsules Product Picture
Figure 5. Injectable Product Picture
Figure 6. Other Product Picture
Figure 7. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Share By Application in 2021 & 2028
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Online Pharmacies
Figure 11. Oculopharyngeal Muscular Dystrophy (OPMD) Report Years Considered
Figure 12. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2017-2028 (K Units)
Figure 13. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2017-2028 (US$ Million)
Figure 15. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 16. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2017-2022)
Figure 17. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2023-2028)
Figure 18. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales YoY (2017-2028) & (K Units)
Figure 19. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales YoY (2017-2028) & (K Units)
Figure 21. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Asia-Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales YoY (2017-2028) & (K Units)
Figure 23. Asia-Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales YoY (2017-2028) & (K Units)
Figure 25. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales YoY (2017-2028) & (K Units)
Figure 27. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue YoY (2017-2028) & (US$ Million)
Figure 28. The Oculopharyngeal Muscular Dystrophy (OPMD) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 29. The Top 5 and 10 Largest Manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) in the World: Market Share by Oculopharyngeal Muscular Dystrophy (OPMD) Revenue in 2021
Figure 30. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 31. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2028)
Figure 32. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Type (2017-2028)
Figure 33. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2028)
Figure 34. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Application (2017-2028)
Figure 35. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2028)
Figure 36. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Type (2017-2028)
Figure 37. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2028)
Figure 38. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Application (2017-2028)
Figure 39. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Country (2017-2028)
Figure 40. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Country (2017-2028)
Figure 41. United States Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 42. Canada Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 43. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2028)
Figure 44. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Type (2017-2028)
Figure 45. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2028)
Figure 46. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Application (2017-2028)
Figure 47. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Country (2017-2028)
Figure 48. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Country (2017-2028)
Figure 49. Germany Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 50. France Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 51. U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 52. Italy Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 53. Russia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 54. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2028)
Figure 55. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Type (2017-2028)
Figure 56. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2028)
Figure 57. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Application (2017-2028)
Figure 58. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Region (2017-2028)
Figure 59. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Region (2017-2028)
Figure 60. China Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 61. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 62. South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 63. India Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 64. Australia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 65. China Taiwan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 66. Indonesia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 67. Thailand Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 68. Malaysia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 69. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2028)
Figure 70. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Type (2017-2028)
Figure 71. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2028)
Figure 72. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Application (2017-2028)
Figure 73. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Country (2017-2028)
Figure 74. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Country (2017-2028)
Figure 75. Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 76. Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 77. Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2028)
Figure 79. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Type (2017-2028)
Figure 80. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2028)
Figure 81. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Application (2017-2028)
Figure 82. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Country (2017-2028)
Figure 84. Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (2017-2028) & (US$ Million)
Figure 87. Oculopharyngeal Muscular Dystrophy (OPMD) Value Chain
Figure 88. Oculopharyngeal Muscular Dystrophy (OPMD) Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed